Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CDX1307 · 2 trials · 5 indications
| Name | Type | Description |
|---|---|---|
| CDX-1307 | BIOLOGICAL | - |
| CDX1307 | BIOLOGICAL | - |
Inclusion Criteria 1. Patients must have incurable, metastatic or unresectable locally advanced breast, colorectal, pancreatic, bladder or ovarian cancer with measurable or evaluable-only disease. Locally advanced breast cancer is defined as inflammatory breast cancer with biopsy-proven skin involv...
Top 20 of 87 competitors
CDX1307 is an investigational monoclonal antibody developed by Celldex Therapeutics, Inc. for the treatment of cancer. It was studied in Phase 1 clinical trials in patients with incurable solid tumors, including breast cancer, colorectal cancer, pancreatic cancer, ovarian cancer, and bladder cancer. It is not an approved therapy.
CDX1307 was studied in Phase 1 trials as a treatment for incurable breast cancer, along with colorectal, pancreatic, ovarian, and bladder cancers. The trials enrolled patients with locally advanced or metastatic disease. It remains an investigational agent and is not approved for breast cancer or any other indication.
CDX1307 was developed by Celldex Therapeutics, Inc., a biopharmaceutical company that trades under the ticker CLDX. Celldex sponsored the Phase 1 clinical program evaluating the antibody in patients with advanced solid tumors, including breast cancer.
CDX1307 is in Phase 1. Two Phase 1 trials were conducted, and both are now completed. No active trials are ongoing. The studies together enrolled 84 patients and evaluated CDX1307 in incurable breast, colorectal, pancreatic, ovarian, and bladder cancers.
CDX1307 was evaluated in two completed Phase 1 trials: NCT00709462, which enrolled 48 patients with incurable breast, colorectal, pancreatic, ovarian, or bladder cancer, and NCT00648102, which enrolled 36 patients with locally advanced or metastatic forms of those cancers. Both were conducted in the United States.
Yes. CDX1307 and CDX-1307 refer to the same investigational monoclonal antibody from Celldex Therapeutics. The hyphenated spelling appears in the trial titles and registry listings, while the unhyphenated form is also used. Both names describe the same Phase 1 cancer asset.